MYD88 and Burkitt lymphoma: Notably, presence of this supercomplex in patient samples was predictive of response to BTK inhibitors.145MYD88 mutations are also present in 15% of C1 DLBCLs but they are almost exclusively non‐L265P in this group.58 Although L265P and non‐L265P MYD88 mutations differentially affect binding and phosphorylation of IRAK1, they all trigger NF‐κB signaling.144 MYD88 non‐L265P mutations have also been reported in transformed FL146; however, MYD88 mutations were not found in GCB‐DLBCL or BL.144